Pharmaceutical Use of FAM19A5 Involved in Regulating Gliogenesis
AssigneeNeuracle Science Co., Ltd.
InventorsJae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
Life of this patent
Estimating the term…
Abstract
The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
Claims21
1-14. (canceled)
A method of treating a degenerative brain disease, central nervous system disease, and/or central nervous system damage in subject in need thereof, comprising administering to the subject an effective amount of an inhibitor that specifically binds to a family with sequence similarity 19 (FAM19A5) (“anti-FAM19A5 inhibitor”).
A method of determining the expression level of FAM19A5 in a subject having a central nervous system damage, degenerative brain disease, or central nervous system disease, comprising:
- detecting whether the expression level of FAM19A5 from a biological sample obtained from the subject is increased compared to the expression level of FAM19A5 from a normal control by contacting the sample with an inhibitor that specifically binds to FAM19A5 (“anti-FAM19A5 inhibitor) and measuring the expression level of FAM19A5.
Dependencies are inferred from the claim text.